Conflict of Interest

Abstract Presenter
No conflict to declare

Abstract Presenter
No conflict to declare

Abstract Presenter
No conflict to declare

Scientific Planning Committee Member
No conflict to declare

Abstract Presenter
No conflict to declare

Abstract Presenter
Information not provided

Abstract Presenter
No conflict to declare

Abstract Presenter
Information not provided

Speaker
Payment: HCV treatment in vulnerable populations – speaker at national meeting; self developed slides and honorarium; Abbvie; Ad board: Advisory board for COVID vaccine – GSK; travel and honorarium

Abstract Presenter
Information not provided

Abstract Presenter
Information not provided

Abstract Presenter
No conflict to declare

Abstract Presenter
No conflict to declare

Speaker, Scientific Planning Committee Member
No conflict to declare

Central Planning Committee Member, Scientific Planning Committee Member, Abstract Reviewer Co-Chair
No conflict to declare

Abstract Presenter
Information not provided

Speaker
Ad board: ViiV Healthcare – pediatric antiretroviral treatment advisory board member; Grant: Operating grants from Canadian Institutes for Health Research, Ontario HIV Treatment Network

Abstract Presenter
No conflict to declare

Speaker
Payment: Bruker, Hologic, Biomerieux, Copan (Honoraria); Ad Board: Bruker, Hologic, Biomerieux, Copan (Speakers’ Bureau)

Scientific Planning Committee Member
No conflict to declare

Speaker
Grant: DynaVax, GlaxoSmithKline, Merck, Moderna, Pfizer, PATH, Sanofi Pasteur, VBI vaccines, Entos Pharmaceuticals, CanSino Biologics, VIDO

Central Planning Committee Member, Scientific Planning Committee Member, Abstract Reviewer Co-Chair
Payment: Paladin pharmacueticals; British Columbia Lung Foundation; University of British Columbia; Making Education Matter for Everyone (Honoraria); Grant: Vancouver Coastal Health Research Institute/Providence Research

Scientific Planning Committee Member
Payment: Sanofi, GSK, bioMerieux; Ad board: Sequirus

Speaker
Grant: 1) CIHR – for the project ‘Clinical study on the screening of transmissible blood infections in donors’ – reimbursed the clinical laboratory fo the cost of serology testing for transmissible viral diseases
2) Micronostyx for Copan – for the project évaluation de l’autoprolevement pour la détection de VPH en dépistage primaire – provided free of charge dry flocked swabs
3) Roche Diagnostic – provided Cobas PCR media as well as Cobas HPV reagent for the study.
4) Ministère de la Santé et des services sociaux du Québec, direction de la cancérologie. Discussion of the protocole and Financial support for the évaluation (mainly salaries for the research nurses and assistants, and for the laboratory technologists.

Speaker
No conflict to declare

Speaker
No conflict to declare

Speaker, Scientific Planning Committee Member
No conflict to declare

Speaker, Abstract Presenter
Payment: Editor Stipend: Clinical Microbiology Newsletter and Journal of Clinical Microbiology; Other: Voting Member of the CLSI Antimicrobial Susceptiblity Testing Subcommittee and the CLSI Antifungal Susceptiblity Testing Subcommittee

Abstract Presenter
Information not provided

Abstract Presenter
No conflict to declare

Speaker
No conflict to declare

Speaker
Ad Board: CMV Canada medical advisory board member

Abstract Presenter
Information not provided

Scientific Planning Committee Member
No conflict to declare

Scientific Planning Committee Member
Central Planning Committee Member, Scientific Planning Committee Member

Abstract Presenter
Information not provided

Abstract Presenter
No conflict to declare

Abstract Presenter
No conflict to declare

Scientific Planning Committee Member
No conflict to declare

Speaker
No conflict to declare

Central Planning Committee Member, Sponsorship Committee Co-Chair
No conflict to declare

Speaker
Payment: GSK, Gilead Sciences, Novo Nordisk, Abbvie, Lupin; Ad board: GSK, Gilead Sciences, Novo Nordisk, Abbvie

Scientific Planning Committee Member
Payment: I have received honoraria from Hologic Inc. for my time for preparation and delivery of presentations at national meetings.

Abstract Presenter
Information not provided

Abstract Presenter
Information not provided

Speaker
Payment: GSK, Merck, Pfizer, Valeo; Ad Board: GSK, Merck, Moderna, Pfizer, Valeo

Speaker
No conflict to declare

Speaker
Payment: Honorarium from Hologic for talks on Bacterial vaginosis and STI testing self collection, Speaker fee from Alberta Pharmacy association – Lyme talk, Speaker fee from College of family Physicians of Canada – Lyme program; Grants: Grant funding from CIHR, NIH, Genome Atlantic, NSHRF, Dalhousie Pharmacy Endowment fund and Drug Evaluation Alliance of NS; Other: Committees at the provincial and National level including: DEG, CPHLN various committees, NACSTBBIs

Abstract Presenter
No conflict to declare

Scientific Planning Committee Member
Payment: Inflammatix

Central Planning Committee Member
Payment: Ferring Pharmaceuticals – received honoraria for helping to develop educational program, for presentations to Ferring leadership; Ad board: Ferring Pharmaceuticals – Advisory Board participation

Abstract Presenter
No conflict to declare

Central Planning Committee Member, Scientific Planning Committee Member
No conflict to declare

Abstract Presenter
Information not provided

Abstract Presenter
Information not provided

Scientific Planning Committee Member
Payment: Honoraria for editorial mentorship and freelance editorial work for Clinical Infectious Diseases, Infectious Diseases Society of America; travel funding for fungal research, ESCMID, Westerdijk Fungal Biodiversity Institute, Netherlands; travel funding for creation of risk of bias tool for non-pharmacologic pandemic interventions, Pandemic EVIDENCE Collaboration, Kellogg College, University of Oxford, UK; Grants: Co-investigator, CIHR, Prevention of Infections in Cardiac Surgery (NCT02285140); co-investigator, CIHR, AeroVax phase 2 SARS-CoV-2 vaccine clinical trial (NCT06381739); co-investigator, CIHR, optimization of bioinformatics pipelines for avian influenza; principal investigator, McMaster University, Pneumocystis jirovecii diagnostic study; Other: Member, Editorial Advisory Board, Clinical Infectious Diseases; Member, Editorial Board, Journal of Clinical Microbiology

Central Planning Committee Member, Scientific Planning Committee Member
No conflict to declare

Scientific Planning Committee Member
Advisory Board: Moderna

Abstract Presenter
No conflict to declare

Abstract Presenter
No conflict to declare

Abstract Presenter
No conflict to declare

Speaker
No conflict to declare

Speaker
No conflict to declare

Speaker
No conflict to declare

Abstract Presenter
No conflict to declare

Speaker, Central Planning Committee Member
No conflict to declare

Central Planning Committee Member
Payment: GlaxoSmithKline Inc. (Honoraria for leading a workshop on quantitative HBsAg (May – Oct, 2025)), Roche (Funding for travel to a meeting (October, 2024))

Abstract Presenter
No conflict to declare

Speaker
No conflict to declare

Abstract Presenter
Information not provided

Abstract Presenter Information not provided

Scientific Planning Committee Member
No conflict to declare

Scientific Planning Committee Member
Investment: I have stocks in a Group A Strep Vaccine through AVIGASVAX Ltd.

Speaker
No conflict to declare

Central Planning Committee Member, Scientific Planning Committee Member
No conflict to declare

Abstract Presenter
Information not provided

Abstract Presenter
No conflict to declare

Speaker
Payment: Enanta (ad hoc advisory board meeting June 2024); Grant/Trial: Merck (site investigator RCT)

Abstract Presenter
Information not provided

Speaker
Payment: Up-to-Date and the Infectious Diseases Board Review Course; Ad Board: Consultant to PhAST, Iterum Therapeutics, DEEPULL DIAGNOSTICS, Claryx, Inc., Nostics, bioMérieux and CARB-X; Grants: Grants from MicuRx Pharmaceuticals and ImmuCell; Patents: Patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication, a patent on PET imaging of bacterial infection with a PET probe filed, and a patent on an anti-biofilm substance issued.

Speaker
No conflict to declare

Scientific Planning Committee Member
Other: Member of CLSI Microbiology Expert Panel

Speaker, Scientific Planning Committee Member
No conflict to declare

Speaker
No conflict to declare

Speaker
No conflict to declare

Abstract Presenter
No conflict to declare

Central Planning Committee Member, Scientific Planning Committee Co-Chair
Ad board: bioMerieux, Xediton, Abbvie, Ferring

Abstract Presenter
Information not provided

Abstract Presenter
Information not provided

Abstract Presenter
No conflict to declare

Scientific Planning Committee Member
No conflict to declare

Scientific Planning Committee Member, Abstract Presenter
No conflict to declare

Scientific Planning Committee Member
Ad board: Over the last 5 years have participated in Advisory Boards for Merck, Pfizer, GSK, Novartis and Sanofi

Abstract Presenter
Information not provided

Abstract Presenter
No conflict to declare

Abstract Presenter
Information not provided

Speaker, Central Planning Committee Member, Scientific Planning Committee Member
No conflict to declare

Abstract Presenter
No conflict to declare

Speaker
No conflict to declare

Speaker
Funded Grant: Merck Canada-investigator initiated grant, CIHR-coinvestigator

Speaker
No conflict to declare

Abstract Presenter
Grants: Ferring, Rebiotix, Seres, Vedanta, Merck, Sanofi Pasteur, and Edesa within the past 3 years; Othe: Consulting fees from Ferring; Employment and research funding from Qu Biologics

Speaker
No conflict to declare

Abstract Presenter
No conflict to declare

Speaker
No conflict to declare

Scientific Planning Committee Member
No conflict to declare

Speaker, Scientific Planning Committee Member
No conflict to declare

Abstract Presenter
Information not provided

Scientific Planning Committee Member
Grant: Gilead grant to fund HDV national study in which I was a collaborator.

Scientific Planning Committee Member
No conflict to declare

Speaker
No conflict to declare

Speaker
Payment: GSK (Canada); Medscape; Merck (Canada); Moderna; Takeda (Canada); Xediton; Ad board: GSK (Canada); Merck (Canada); Moderna; Takeda (Canada); Xediton; Patent: US patent application 63/056,249 Title: METHODS FOR ASSESSING THE SEVERITY AND PROGRESSION OF SARS-COV-2 INFECTIONS USING CELL-FREE DNA Cornell Reference No: 9561-01-US Filing date: July 24, 2020 US patent filing #: 63/056,249

Abstract Presenter
Information not provided

Speaker, Scientific Planning Committee Member
No conflict to declare

Abstract Presenter
No conflict to declare

Abstract Presenter
No conflict to declare

Abstract Presenter
Information not provided

Speaker, Central Planning Committee Member
Grant: Research grant from BioMerieux to evaluate REVEAL; Patent: Patent Zentek – biosensor platform

Abstract Presenter
No conflict to declare

Speaker
“Payment: 2026 Data Safety and Monitoring Committee (phase 2 vaccine trial) InventVac Inc., 2024 Data Safety and Monitoring Committee (phase 1 vaccine trial) InventVac Inc.(2021-2022 Independent Data Monitoring Committee (phase 3 vaccine trial, outcomes adjudcation) Medicago Inc.; Ad board: (2023-present) CATMAT Voting Member
(2023-2025) CARB-X Advisory panel
(2023-2025) WHO AMR Diagnostic Initiative; Technical working group member (TWG).
(2024-2025) WHO. Expert Group Member (EG). WHO Typhoid Diagnostic Reference Panel (TyDReP) to Assess In Vitro Diagnostics for Typhoid.
(2022-2023) TPP development group for RDT readers World Health Organization & FIND; Grant: Current grants from FRQS (salary and operating), CIHR, MITACS, & PORTENT (NIH)”

Abstract Presenter
No conflict to declare

Scientific Planning Committee Member
No conflict to declare

Speaker
No conflict to declare